Discovery of monocarbonyl curcumin hybrids as a novel class of human DNA ligase I inhibitors: in silico design, synthesis and biology-Reference-Cited by-同舟云学术

Discovery of monocarbonyl curcumin hybrids as a novel class of human DNA ligase I inhibitors: in silico design, synthesis and biology

Published:2016 Issue:31 Volume:6 Page:26003-26018
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Mandalapu Dhanaraju¹²³⁴,Singh Deependra Kumar⁵²³⁴,Gupta Sonal¹²³⁴⁶,Balaramnavar Vishal M.⁵²³⁴,Shafiq Mohammad⁵²³⁴,Banerjee Dibyendu⁵²³⁴⁶,Sharma Vishnu Lal¹²³⁴⁶

Affiliation:

1. Medicinal & Process Chemistry Division

2. CSIR-Central Drug Research Institute (CSIR-CDRI)

3. Lucknow

4. India

5. Molecular & Structural Biology Division

6. Academy of Scientific and Innovative Research (AcSIR)

Abstract

A pharmacophore model identified a novel class of hLigI inhibitors to treat cancer. 36 compounds were synthesized and the identified inhibitor, compound 23 shown antiligase activity at IC₅₀ 24.9 μM by abolishing the interaction between hLigI and DNA.

Funder

Department of Biotechnology , Ministry of Science and Technology

Indian Council of Medical Research

Department of Science and Technology, Ministry of Science and Technology

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2016/RA/C5RA25853G

Reference63 articles.

1. How many drug targets are there?